Brief Overview of Front-line treatment for Mantel Cell Lymphoma in Older Patients

Opinion
Video

Key opinion leaders examine the current frontline treatment options for mantle cell lymphoma while identifying critical unmet patient needs requiring attention.

  1. Briefly discuss the front-line treatment landscape for mantel cell lymphoma? 
  2. What are some unmet needs in this patient population? 
Related Videos
relapsed or refractory mantle cell lymphoma, glofitamab, Obinutuzumab, phase 1/2 study, NCT03075696, Tycel J. Phillips, MD
Amrita Y. Krishnan, MD, and Binod Dhakal, MD
Amrita Y. Krishnan, MD, and Binod Dhakal, MD
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
This series features 2 KOLs.
4 KOLs are featured in this panel.
4 KOLs are featured in this panel.
4 KOLs are featured in this program.
Related Content
Findings from ELM-1 and ELM-2 support the positive opinion for odronextamab as a treatment for relapsed/refractory follicular lymphoma and DLBCL.

EU’s CHMP Recommends Odronextamab Approval in Follicular Lymphoma, DLBCL

Russ Conroy
July 1st 2024
Article

Findings from ELM-1 and ELM-2 support the positive opinion for odronextamab as a treatment for relapsed/refractory follicular lymphoma and DLBCL.

The Lymphoma Research Foundation MCL Scientific Consortium and Workshop focused on relevant topics that can help clinicians personalize treatment for patients.

Unraveling Resistance and Heterogeneity in Mantle Cell Lymphoma Management

Elias Campo, MD, PhD;Michael Wang, MD;Martin Dreyling, MD;Julie M. Vose, MD, MBA
February 5th 2024
Podcast

The Lymphoma Research Foundation MCL Scientific Consortium and Workshop focused on relevant topics that can help clinicians personalize treatment for patients.

Findings from the EPCORE NHL-1 trial support the FDA approval of epcoritamab in relapsed/refractory follicular lymphoma.

FDA Grants Accelerated Approval to Epcoritamab in R/R Follicular Lymphoma

Roman Fabbricatore;Russ Conroy
June 26th 2024
Article

Findings from the EPCORE NHL-1 trial support the FDA approval of epcoritamab in relapsed/refractory follicular lymphoma.

Expert oncologist/hematologists Bruce Cheson, MD, FACP, and Steven Park, MD, discuss findings from the E7438-G000-101 trial and consider the efficacy of tazemetostat as treatment for relapsed or refractory follicular lymphoma.

Between the Lines Podcast: Tazemetostat in Relapsed/Refractory Follicular Lymphoma

Bruce D. Cheson, MD;Steven Park, MD
November 3rd 2022
Podcast

Expert oncologist/hematologists Bruce Cheson, MD, FACP, and Steven Park, MD, discuss findings from the E7438-G000-101 trial and consider the efficacy of tazemetostat as treatment for relapsed or refractory follicular lymphoma.

Outpatient CAR T-Cell Therapy Is Feasible, Safe for Non-Hodgkin Lymphoma

Outpatient CAR T-Cell Therapy Is Feasible, Safe for Non-Hodgkin Lymphoma

Tony Berberabe, MPH
June 14th 2024
Article

Administering CAR T-cell therapy in an outpatient setting to patients with relapsed/refractory non-Hodgkin lymphoma was deemed feasible and safe.

Brentuximab Vedotin Improves Efficacy in Classical Hodgkin Lymphoma

Brentuximab Vedotin Improves Efficacy in Classical Hodgkin Lymphoma

Brielle Benyon
June 1st 2024
Article

Brentuximab vedotin led to unprecedented progression-free survival for patients with classical Hodgkin lymphoma.